Survival in patients with glioblastoma receiving valganciclovir.
about
Immunotherapy advances for glioblastomaCytomegalovirus in human brain tumors: Role in pathogenesis and potential treatment optionsImmunoglobulin GM Genes, Cytomegalovirus Immunoevasion, and the Risk of Glioma, Neuroblastoma, and Breast CancerManagement of Viral Central Nervous System Infections: A Primer for CliniciansCytomegalovirus Restructures Lipid Rafts via a US28/CDC42-Mediated Pathway, Enhancing Cholesterol Efflux from Host Cells.History and current state of immunotherapy in glioma and brain metastasis.Evolution of malignant glioma treatment: from chemotherapy to vaccines to viruses.Human cytomegalovirus tegument protein pp65 is detected in all intra- and extra-axial brain tumours independent of the tumour type or gradeHuman cytomegalovirus infection in tumor cells of the nervous system is not detectable with standardized pathologico-virological diagnostics.The oncomodulatory role of human cytomegalovirus in colorectal cancer: implications for clinical trials.The Viral Connection to Glioblastoma.High prevalence of human cytomegalovirus in brain metastases of patients with primary breast and colorectal cancers.Prevalence of human cytomegalovirus, polyomaviruses, and oncogenic viruses in glioblastoma among Japanese subjects.The future of high-grade glioma: Where we are and where are we going.Identification and HLA-tetramer-validation of human CD4+ and CD8+ T cell responses against HCMV proteins IE1 and IE2.Discordant humoral and cellular immune responses to Cytomegalovirus (CMV) in glioblastoma patients whose tumors are positive for CMV.α-Carboline derivative TJY-16 inhibits tumor growth by inducing G2/M cell cycle arrest in glioma cells.Absence of human cytomegalovirus infection in childhood brain tumors.Is CMV a target in pediatric glioblastoma? Expression of CMV proteins, pp65 and IE1-72 and CMV nucleic acids in a cohort of pediatric glioblastoma patients.Cytomegalovirus infection induces a stem cell phenotype in human primary glioblastoma cells: prognostic significance and biological impactA comprehensive next generation sequencing-based virome assessment in brain tissue suggests no major virus - tumor association.US28, a Virally-Encoded GPCR as an Antiviral Target for Human Cytomegalovirus Infection.CMV infection and glioma, a highly controversial concept struggling in the clinical arenaCancer as a metabolic disease: implications for novel therapeutics.Treatment of cytomegalovirus infections beyond acute disease to improve human health.Herpesvirus-encoded GPCRs: neglected players in inflammatory and proliferative diseases?Design and development of antivirals and intervention strategies against human herpesviruses using high-throughput approach.Cytomegalovirus as a novel target for immunotherapy of glioblastoma multiforme.Human cytomegalovirus antigens in malignant gliomas as targets for adoptive cellular therapyCytomegalovirus and glioblastoma; controversies and opportunities.Human Cytomegalovirus-Infected Glioblastoma Cells Display Stem Cell-Like Phenotypes.Expanding role of cytomegalovirus as a human pathogen.Lack of human cytomegalovirus expression in single cells from glioblastoma tumors and cell lines.Cytomegalovirus and immunotherapy: opportunistic pathogen, novel target for cancer and a promising vaccine vector.Overexpression of CPEB4 in glioma indicates a poor prognosis by promoting cell migration and invasion.Absence of Cytomegalovirus in Glioblastoma and Other High-grade Gliomas by Real-time PCR, Immunohistochemistry, and In Situ Hybridization.Plexin-B1 indirectly affects glioma invasiveness and angiogenesis by regulating the RhoA/αvβ3 signaling pathway and SRPK1.Hijacking GPCRs by viral pathogens and tumor.Enhanced neutrophil activity is associated with shorter time to tumor progression in glioblastoma patients.Does Regular Exercise Counter T Cell Immunosenescence Reducing the Risk of Developing Cancer and Promoting Successful Treatment of Malignancies?
P2860
Q26866513-6B3BB97A-68DE-4CC9-AD6C-CF61145C13EAQ26996612-105AFC4C-7661-4C08-A8B3-0CB614A2F2FAQ28393259-84A7FC7D-F22E-4361-B79A-CB861DD043BAQ30145523-762F3FC6-F724-42E4-A014-EEB7440AAA4DQ33557172-0F89CAD2-BFD4-44FD-8821-E3E379B5FF1AQ33656811-AD7FAE99-5C66-4FEF-88D6-586AD3DFA717Q33923950-B7A24DC7-AF2B-42AC-8AB4-58C921A17A36Q34277652-BDEBF315-83A3-48A5-9EAB-24C2F4A8D43AQ34359722-E1B4030A-21FF-4157-9126-17DC555B5882Q34521746-15D1AAEE-F3CE-4333-80C5-3DCEA396547CQ34552036-522EAEA7-8008-4FBE-BCE3-82E979672F40Q35028835-DE4E5A5A-659D-4BC0-A24C-A2663351775BQ35083935-AA419EBF-8BC0-47CF-8396-BE8F63EFFA49Q35114090-70BCA495-EAE8-4D9A-9B6F-1DC97DAA1FDCQ35156297-DEAD8576-0C42-4A02-9310-860D93FB0380Q35506920-28D2F5D6-AA2A-476D-B82C-454411D9923BQ35898306-E850100C-16AF-46B6-9FDD-45AD8ECC4CC9Q36057137-7E0ABBC8-9285-4668-95ED-26A5C3D52629Q36181306-7898E047-B5B8-4A23-9757-5EA5E4BB4B46Q36472483-7F66CEA6-B5F0-4C0D-B9C6-130F70A89A74Q37085029-CEC108C4-44EE-4070-8E1F-B815E446EBCBQ37551927-9EAACF94-AE14-405C-B50C-51EDB465B376Q37580512-E54DB7AF-D266-4854-89DD-BE9825F688E7Q37616057-D12F41A5-26BA-4031-8379-8E7F7BF0A2F2Q38176940-C7948E41-7CCF-4A5A-BD8E-15691D4CE38CQ38180332-47BE3A6A-8478-4E41-BAE7-C314980E2417Q38227257-9A2CB642-4058-496E-BA0A-85644D4E3D02Q38262132-FAC98816-1987-4C08-8819-27E8DC182676Q38288049-4AB73652-C332-415E-8C72-E797548FFA7BQ38355706-61FB282C-08B1-4A4F-BFFE-640767F574E6Q38665860-5AEB53E3-BD32-4B22-AD5E-FFC9178146FEQ38673038-7C2D8F84-E70D-4227-A7A5-B693B79ADC79Q38684797-595B1225-7AFC-4AB0-A59F-34F159A0CDA9Q38703382-E433BCFE-C6D2-4BF4-BE03-F06659B22FA9Q38708764-0E7413AD-D7FD-4C64-A920-7FA47148908CQ38776409-73272739-3D56-4339-8CE8-48EF12477F86Q38788887-2F2E4A75-5598-42B5-81B1-2AF74B1A5768Q38802773-500852EC-4359-4CF0-89BB-524F344CBAFEQ39279856-23680529-CFF1-4ABA-9F7C-91C5C7E2674AQ40104771-BEBADFDB-38E8-456E-9B91-D24F6EB8DB38
P2860
Survival in patients with glioblastoma receiving valganciclovir.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Survival in patients with glioblastoma receiving valganciclovir.
@en
Survival in patients with glioblastoma receiving valganciclovir.
@nl
type
label
Survival in patients with glioblastoma receiving valganciclovir.
@en
Survival in patients with glioblastoma receiving valganciclovir.
@nl
prefLabel
Survival in patients with glioblastoma receiving valganciclovir.
@en
Survival in patients with glioblastoma receiving valganciclovir.
@nl
P50
P356
P1476
Survival in patients with glioblastoma receiving valganciclovir.
@en
P304
P356
10.1056/NEJMC1302145
P407
P577
2013-09-01T00:00:00Z